• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cyclerion Therapeutics, Inc. - Common Stock (NQ:CYCN)

1.410 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cyclerion Therapeutics, Inc. - Common Stock

News headline image
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
February 17, 2026
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
January 06, 2026
Via AB Newswire
News headline image
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
January 05, 2026
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
September 23, 2025
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
December 17, 2024
Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat 
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Regina Graul, Ph.D., Promoted to Chief Executive Officer
August 07, 2024
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Appoints Regina Graul, Ph.D., as President
December 04, 2023
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
November 30, 2023
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
July 31, 2023
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 01, 2023
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Announces Reverse Stock Split
May 15, 2023
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
May 11, 2023
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
May 11, 2023
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
April 03, 2023
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
March 27, 2023
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
March 22, 2023
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
November 22, 2022
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
October 06, 2022
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
July 28, 2022
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
July 26, 2022
Renowned neuroscience leader to further long-term clinical research strategy and external collaborations 
From Cyclerion Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap